New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00035854|
Recruitment Status : Completed
First Posted : May 7, 2002
Last Update Posted : August 14, 2009
|Condition or disease||Intervention/treatment||Phase|
|Bacterial Infections||Drug: Zyvox® / Linezolid||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Linezolid IV/PO for the Treatment of Vancomycin-Resistant Enterococcus Infections in Children|
|Study Start Date :||February 2002|
|Actual Study Completion Date :||May 2004|
- Investigator's and sponsor's evaluation of patient clinical outcome.
- Pathogen eradication rates, changes in clinical signs and symptoms, body temperature, WBC count, lesion size (for SSSIs) and chest radiograph findings(for HAP).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035854
Show 21 Study Locations